Prognostic factors for COVID-19 patients

Authors

  • Uğur Önal Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Özge Aydın Güçlü Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Halis Akalın Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Nilüfer Aylin Acet Öztürk Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Cihan Semet Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Ezgi Demirdöğen Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Aslı Görek Dilektaşlı Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey
  • İmran Sağlık Department of Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Esra Kazak Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Güven Özkaya Department of Biostatistics, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Funda Coşkun Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Dane Ediger Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Yasemin Heper Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Ahmet Ursavaş Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Emel Yılmaz Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Esra Uzaslan Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey
  • Mehmet Karadağ Department of Pulmonary Diseases, Faculty of Medicine, Uludag University, Bursa, Turkey

DOI:

https://doi.org/10.3855/jidc.15845

Keywords:

COVID-19, prognostic factors, SOFA, CURB-65

Abstract

Introduction: Determining prognostic factors in patients with coronavirus disease (COVID-19) can have great impact on treatment planning and follow-up strategies. Herein, we aimed to evaluate prognostic factors and clinical scores for confirmed COVID-19 patients in a tertiary-care hospital in the Bursa region of Turkey.

Methodology: Patients who had been diagnosed with COVID-19 microbiologically and/or radiologically between March and October 2020 in a tertiary-care university hospital were enrolled retrospectively. Adult patients (≥ 18 years) with a clinical spectrum of moderate, severe, or critical illness were included. The dependent variable was 30-day mortality and logistic regression analysis was used to evaluate any variables with a significant p value (< 0.05) in univariate analysis.

Results: A total of 257 patients were included in the study. The mortality rate (30-day) was 14.4%. In logistic regression analysis, higher scores on sequential organ failure assessment (SOFA) (p < 0.001, odds ratio (OR) = 1.86, 95% CI = 1.42-2.45) and CURB-65 pneumonia severity criteria (p = 0.001, OR = 2.60, 95% CI = 1.47-4.57) were found to be significant in predicting mortality at admission. In deceased patients, there were also significant differences between the baseline, day-3, day-7, and day-14 results of D-dimer (p = 0.01), ferritin (p = 0.042), leukocyte (p = 0.019), and neutrophil (p = 0.007) counts.

Conclusions: In our study of COVID-19 patients, we found that high SOFA and CURB-65 scores on admission were associated with increased mortality. In addition, D-dimer, ferritin, leukocyte and neutrophil counts significantly increased after admission in patients who died.

Downloads

Published

2022-03-31

How to Cite

1.
Önal U, Aydın Güçlü Özge, Akalın H, Aylin Acet Öztürk N, Semet C, Demirdöğen E, Görek Dilektaşlı A, Sağlık İmran, Kazak E, Özkaya G, Coşkun F, Ediger D, Heper Y, Ursavaş A, Yılmaz E, Uzaslan E, Karadağ M (2022) Prognostic factors for COVID-19 patients. J Infect Dev Ctries 16:409–417. doi: 10.3855/jidc.15845

Issue

Section

Coronavirus Pandemic